Twigman,
You are obviously well informed and know a lot about the subject. however you are missing the point of the Cpn10 study. It was small because that was all the drug available and the company did not have funds to manufacture more drug. The object of the study was to prove safety at larger doses and to show a dose response with increasing dose. Both these objects were reached. dose was increased ten fold and dose response was demonstrated. this is still an early stage drug, but given the work in London demonstrating that Cpn 10 is one of the hypothesised RAMPs, and the only one with substantial work on it, this is a valuable property. Just wait a couple of months and you will see that there is a high interest from more than one large pharma.
IVX Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)